Based on the Tempest Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Tempest Therapeutics Inc is USD 8.67 over the next 12 months. Tempest Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Tempest Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Tempest Therapeutics Inc’s stock price was USD 0.91. Tempest Therapeutics Inc’s stock price has changed by +1.75% over the past week, -13.76% over the past month and -78.39% over the last year.
No recent analyst target price found for Tempest Therapeutics Inc
No recent average analyst rating found for Tempest Therapeutics Inc
Company Overview Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. Read Less
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, recept...Read More
Frequently Asked Questions About Tempest Therapeutics Inc (TPST) Stock
Based on ratings from 2 analysts Tempest Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on TPST's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for TPST is USD 8.67 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 5.
TPST stock's Price/Earning ratio is 0.20.
Our analysis grades TPST stock's Price / Earning ratio at B. This means that TPST stock's Price/Earning ratio is above 17% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TPST may be undervalued for its sector.
The last closing price of TPST's stock was USD 0.91.
The most recent market capitalization for TPST is USD 0.02B.
Based on targets from 2 analysts, the average taret price for TPST is projected at USD 8.67 over the next 12 months.
This means that TPST's stock price may go up by +857.11% over the next 12 months.
We can't find any ETFs which contains Tempest Therapeutics Inc's stock.
As per our most recent records Tempest Therapeutics Inc has 17 Employees.
Tempest Therapeutics Inc's registered address is 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005.
You can get more information about it from Tempest Therapeutics Inc's website at https://www.tempesttx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Tempest Therapeutics Inc (TPST) Stock
Based on ratings from 2 analysts Tempest Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on TPST's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for TPST is USD 8.67 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 5.
TPST stock's Price/Earning ratio is 0.20.
Our analysis grades TPST stock's Price / Earning ratio at B. This means that TPST stock's Price/Earning ratio is above 17% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TPST may be undervalued for its sector.
The last closing price of TPST's stock was USD 0.91.
The most recent market capitalization for TPST is USD 0.02B.
Based on targets from 2 analysts, the average taret price for TPST is projected at USD 8.67 over the next 12 months.
This means that TPST's stock price may go up by +857.11% over the next 12 months.
We can't find any ETFs which contains Tempest Therapeutics Inc's stock.
As per our most recent records Tempest Therapeutics Inc has 17 Employees.
Tempest Therapeutics Inc's registered address is 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005.
You can get more information about it from Tempest Therapeutics Inc's website at https://www.tempesttx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TPST !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
